Cargando…

Efficacy and Safety of Sofosbuvir and Ledipasvir for Hepatitis C in Kidney Transplant Recipients: A Single-center Retrospective Observational Study

BACKGROUND: Treatment using direct-acting antivirals provides high rates of sustained virologic response and a favorable safety profile for patients with chronic hepatitis C virus infection. However, data on the efficacy of direct-acting antivirals in kidney transplant recipients are still limited....

Descripción completa

Detalles Bibliográficos
Autores principales:	Artan, Ayşe Serra, Mirioğlu, Şafak, İstemihan, Zulal, Aksoy, Elif, Dirim, Ahmet Burak, Çavuş, Bilger, Oto, Özgür Akın, Çifçibaşı-Örmeci, Aslı, Beşışık, Fatih, Çalışkan, Yaşar, Öztürk, Savaş, Yazıcı, Halil, Kaymakoğlu, Sabahattin, Türkmen, Aydın
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175878/ https://www.ncbi.nlm.nih.gov/pubmed/36960943 http://dx.doi.org/10.4274/balkanmedj.galenos.2023.2022-10-13

Ejemplares similares

A mysterious cause of recurrent acute liver dysfunction for over a decade
por: Dirim, Ahmet Burak, et al.
Publicado: (2021)

Successful treatment of a COVID-19 patient with thrombotic microangiopathy
por: Safak, Seda, et al.
Publicado: (2021)

Risk factors associated with progression to intestinal complications of Crohn disease
por: Kayar, Yusuf, et al.
Publicado: (2019)

Outcomes of kidney transplantation in patients with congenital anomalies of the kidney and urinary tract: a propensity-score-matched analysis with case-control design
por: OTO, Özgür Akın, et al.
Publicado: (2023)

Cell-free methylation of RASSF1 and CDKN2AIP genes in the diagnosis of hepatocellular carcinoma associated with hepatitis B virus cirrhosis
por: Telli, Pelin, et al.
Publicado: (2022)

Is there any predictor for relapse after treatment withdrawal in autoimmune hepatitis patients in the real life?
por: Çavuş, Bilger, et al.
Publicado: (2022)

Retention during capsule endoscopy: Is it a real problem in routine practice?
por: Ormeci, Asli Cifcibasi, et al.
Publicado: (2016)

Is the Y90-radioembolization treatment effective on the intermediate-advanced stage of hepatocellular carcinoma and what is the albumin-bilirubin score’s prediction factor for survival?
por: Evirgen, Sami, et al.
Publicado: (2023)

The effect of liver test abnormalities on the prognosis of COVID-19
por: Medetalibeyoglu, Alpay, et al.
Publicado: (2020)

Impact of the COVID-19 pandemic on interest in renal diseases
por: Oto, Ozgur Akin, et al.
Publicado: (2021)

Evaluation of safety and efficacy of tenofovir disoproxil in hemodialysis and renal transplant patients monoinfected with hepatitis B virus based on real life data
por: Akyüz, Filiz, et al.
Publicado: (2022)

Current state and clinical outcome in Turkish patients with hepatocellular carcinoma
por: Ekinci, Omer, et al.
Publicado: (2018)

Minimal change disease following vaccination with CoronaVac
por: Dirim, Ahmet Burak, et al.
Publicado: (2021)

New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir
por: Premji, Resmi, et al.
Publicado: (2015)

Palisaded neutrophilic and granulomatous dermatitis associated with ledipasvir/sofosbuvir
por: Shenk, Mary Elizabeth Reed, et al.
Publicado: (2018)

Belching in Irritable Bowel Syndrome: An Impedance Study
por: Obekli, Tuba, et al.
Publicado: (2017)

Page Kidney: A Rare Cause of Resistant Hypertension Early After Renal Transplantation
por: Dirim, Ahmet Burak, et al.
Publicado: (2021)

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2017)

Real‐world safety and efficacy of sofosbuvir and ledipasvir for elderly patients
por: Tamai, Hideyuki, et al.
Publicado: (2018)

Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy
por: Janjua, Naveed Z., et al.
Publicado: (2019)

Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2018)

Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV
por: Tadokoro, Tomoko, et al.
Publicado: (2017)

Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus
por: Ansari, Umer, et al.
Publicado: (2017)

Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection
por: Nirei, Kazushige, et al.
Publicado: (2017)

The effectiveness of oral antiviral (Sofosbuvir/Ledipasvir) in treating children with HCV infection
por: Alkaaby, Ban Adil, et al.
Publicado: (2018)

Drug-induced lung disease adverse effect with Ledipasvir Acetonate/Sofosbuvir
por: Omotani, Sachiko, et al.
Publicado: (2020)

Mucocutaneous Manifestations and Associated Factors in Patients with Crohn’s Disease
por: Kayar, Yusuf, et al.
Publicado: (2022)

Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C
por: O'Brien, Thomas R., et al.
Publicado: (2014)

Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
por: Sundaram, Vinay, et al.
Publicado: (2016)

Early and late changes in natural killer cells in response to ledipasvir/sofosbuvir treatment
por: Golden‐Mason, Lucy, et al.
Publicado: (2018)

Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population
por: Stewart, Rachel A., et al.
Publicado: (2018)

Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C
por: Naylor, Paul H, et al.
Publicado: (2017)

Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir
por: Younossi, Zobair M., et al.
Publicado: (2016)

Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C
por: Saab, Sammy, et al.
Publicado: (2017)

Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient
por: Thalhammer, Julian, et al.
Publicado: (2021)

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany
por: Buggisch, Peter, et al.
Publicado: (2019)

Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection
por: Wang, Gary P., et al.
Publicado: (2018)

Reply: Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C
por: O’Brien, Thomas R., et al.
Publicado: (2015)

Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir
por: Younossi, Zobair M., et al.
Publicado: (2016)

Miliary tuberculosis infection during hepatitis C treatment with sofosbuvir and ledipasvir plus ribavirin
por: Ballester-Ferré, Maria Pilar, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1a5743a5q0b4nj92c47ese5fg5